Exact Mass: 472.2508
Exact Mass Matches: 472.2508
Found 500 metabolites which its exact mass value is equals to given mass value 472.2508
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Lucidenic acid K
Lucidenic acid K is found in mushrooms. Lucidenic acid K is a constituent of Ganoderma lucidum (reishi) Constituent of Ganoderma lucidum (reishi). Lucidenic acid K is found in mushrooms. Lucidenic acid K is a triterpenoid.
Chenodeoxycholic acid sulfate
The sulfate salt of Chenodeoxycholic acid is one of the 4 main organic acids produced by the liver. (Wikipedia). The sulfate salt of Chenodeoxycholic acid is one of the 4 main organic acids produced by the liver. [HMDB]
Chenodeoxycholic acid 3-sulfate
Chenodeoxycholic acid 3-sulfate is produced by the action of enzymes existing in the microbial flora of the colonic environment. The major phase II metabolism of bile acids is sulfation mainly catalyzed by the hydroxysteroid sulfotransferase, forming the 3-sulfate conjugate. (PMID:16949895) [HMDB] Chenodeoxycholic acid 3-sulfate is produced by the action of enzymes existing in the microbial flora of the colonic environment. The major phase II metabolism of bile acids is sulfation mainly catalyzed by the hydroxysteroid sulfotransferase, forming the 3-sulfate conjugate. (PMID: 16949895). D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
Ursodeoxycholic acid 3-sulfate
Ursodeoxycholic acid is produced by the action of enzymes existing in the microbial flora of the colonic environment. The major phase II metabolism of bile acids is sulfation mainly catalyzed by the hydroxysteroid sulfotransferase, forming the 3-sulfate conjugate. (PMID:16949895) [HMDB] Ursodeoxycholic acid is produced by the action of enzymes existing in the microbial flora of the colonic environment. The major phase II metabolism of bile acids is sulfation mainly catalyzed by the hydroxysteroid sulfotransferase, forming the 3-sulfate conjugate. (PMID: 16949895).
(2R,4S)-4-Carbamimidamido-3-acetamido-2-((1R,2R)-2-hydroxy-1-methoxy-3-(octanoyloxy)propyl)-3,4-dihydro-2H-pyran-6-carboxylic acid
Linagliptin
Methylprednisolone aceponate
3-Ketopetromyzonol sulfate
20-O-Acetylingenol-3-angelate
13-(acetyloxy)-1-hydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl (2E)-2-methylbut-2-enoate
20-Deoxy,16-acetoxy,3-angeloyl-Ingenol|20-deoxy-16-hydroxyingenol-16-acetate-3-angelate
(+/-)-3-[(2E,6E,10E)-11-carboxy-13-hydroxy-3,7,15-trimethyl-2,6,10,14-hexadecatetraenyl]-4,5-dihydroxybenzoic acid
(1R*,2R*,5Z,10R*,11S*,12R*,14S*)-14-acetoxy-11,12-epoxy-3-oxobriara-5,7,17-trien-2-yl 3-methylbutanoate
longipin-2-ene-7beta-acetyloxy-9alpha-senecioyloxy-15-angeloyloxy-1-one
12-O-[3-methyl-2-butenoyl]-4-deoxyphorbol 13-acetate
7beta,9alpha-diangeloyloxy-8alpha-acetyloxylongipin-2-en-1-one
longipin-2-ene-7beta-acetyloxy-9alpha,15-diangeloyloxy-1-one
(+/-)-3-[(2E,6E,10E)-11-carboxy-14-hydroxy-3,7,15-trimethyl-2,6,10,15-hexadecatetraenyl]-4,5-dihydroxybenzoic acid
Linagliptin
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
C27H36O7_2-Butenoic acid, 2-methyl-, 9a-(acetyloxy)-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-7b-hydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1H-cyclopropa[3,4]benz[1,2-e]azulen-9-yl ester, (2E)
3Alpha-Hydroxy-3-Deoxyangolensic Acid Methyl Ester
3a-Sulfooxy-7a-OH-5b-cholanic acid
BA-140-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-140-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-140-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-140-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
13-(acetyloxy)-1-hydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl (2E)-2-methylbut-2-enoate_major
3-Deoxy-3Beta-Hydroxyangolensic Acid Methyl Ester_major
(4R)-4-((3R,5R,8R,9S,10S,12S,13R,17R)-12-hydroxy-10,13-dimethyl-3-(sulfooxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
(4R)-4-((3R,5R,7R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-(sulfooxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
13-(acetyloxy)-1-hydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,?.0¹¹,¹³]pentadeca-3,8-dien-14-yl (2E)-2-methylbut-2-enoate
Ala Phe His Val
Ala Phe Val His
Ala His Phe Val
Ala His Val Phe
Ala Val Phe His
Ala Val His Phe
Phe Ala His Val
Phe Ala Val His
Phe Gly His Ile
Phe Gly His Leu
Phe Gly Ile His
Phe Gly Leu His
Phe His Ala Val
Phe His Gly Ile
Phe His Gly Leu
Phe His Ile Gly
Phe His Leu Gly
Phe His Val Ala
Phe Ile Gly His
Phe Ile His Gly
Phe Ile Pro Pro
Phe Leu Gly His
Phe Leu His Gly
Phe Leu Pro Pro
Phe Pro Ile Pro
Phe Pro Leu Pro
Phe Pro Pro Ile
Phe Pro Pro Leu
Phe Val Ala His
Phe Val His Ala
Gly Phe His Ile
Gly Phe His Leu
Gly Phe Ile His
Gly Phe Leu His
Gly His Phe Ile
Gly His Phe Leu
Gly His Ile Phe
Gly His Leu Phe
Gly Ile Phe His
Gly Ile His Phe
Gly Leu Phe His
Gly Leu His Phe
His Ala Phe Val
His Ala Val Phe
His Phe Ala Val
His Phe Gly Ile
His Phe Gly Leu
His Phe Ile Gly
His Phe Leu Gly
His Phe Val Ala
His Gly Phe Ile
His Gly Phe Leu
His Gly Ile Phe
His Gly Leu Phe
His Ile Phe Gly
His Ile Gly Phe
His Leu Phe Gly
His Leu Gly Phe
His Val Ala Phe
His Val Phe Ala
Ile Phe Gly His
Ile Phe His Gly
Ile Phe Pro Pro
Ile Gly Phe His
Ile Gly His Phe
Ile His Phe Gly
Ile His Gly Phe
Ile Ile Asn Asn
Ile Leu Asn Asn
Ile Asn Ile Asn
Ile Asn Leu Asn
Ile Asn Asn Ile
Ile Asn Asn Leu
Ile Asn Gln Val
Ile Asn Val Gln
Ile Pro Phe Pro
Ile Pro Pro Phe
Ile Gln Asn Val
Ile Gln Val Asn
Ile Val Asn Gln
Ile Val Gln Asn
Lys Pro Gln Thr
Lys Pro Thr Gln
Lys Gln Pro Thr
Lys Gln Thr Pro
Lys Thr Pro Gln
Lys Thr Gln Pro
Leu Phe Gly His
Leu Phe His Gly
Leu Phe Pro Pro
Leu Gly Phe His
Leu Gly His Phe
Leu His Phe Gly
Leu His Gly Phe
Leu Ile Asn Asn
Leu Leu Asn Asn
Leu Asn Ile Asn
Leu Asn Leu Asn
Leu Asn Asn Ile
Leu Asn Asn Leu
Leu Asn Gln Val
Leu Asn Val Gln
Leu Pro Phe Pro
Leu Pro Pro Phe
Leu Gln Asn Val
Leu Gln Val Asn
Leu Val Asn Gln
Leu Val Gln Asn
Asn Ile Ile Asn
Asn Ile Leu Asn
Asn Ile Asn Ile
Asn Ile Asn Leu
Asn Ile Gln Val
Asn Ile Val Gln
Asn Leu Ile Asn
Asn Leu Leu Asn
Asn Leu Asn Ile
Asn Leu Asn Leu
Asn Leu Gln Val
Asn Leu Val Gln
Asn Asn Ile Ile
Asn Asn Ile Leu
Asn Asn Leu Ile
Asn Asn Leu Leu
Asn Pro Arg Ser
Asn Pro Ser Arg
Asn Gln Ile Val
Asn Gln Leu Val
Asn Gln Val Ile
Asn Gln Val Leu
Asn Arg Pro Ser
Asn Arg Ser Pro
Asn Ser Pro Arg
Asn Ser Arg Pro
Asn Val Ile Gln
Asn Val Leu Gln
Asn Val Gln Ile
Asn Val Gln Leu
Pro Phe Ile Pro
Pro Phe Leu Pro
Pro Phe Pro Ile
Pro Phe Pro Leu
Pro Ile Phe Pro
Pro Ile Pro Phe
Pro Lys Gln Thr
Pro Lys Thr Gln
Pro Leu Phe Pro
Pro Leu Pro Phe
Pro Asn Arg Ser
Pro Asn Ser Arg
Pro Pro Phe Ile
Pro Pro Phe Leu
Pro Pro Ile Phe
Pro Pro Leu Phe
Pro Pro Pro Tyr
Pro Pro Tyr Pro
Pro Gln Lys Thr
Pro Gln Thr Lys
Pro Arg Asn Ser
Pro Arg Ser Asn
Pro Ser Asn Arg
Pro Ser Arg Asn
Pro Thr Lys Gln
Pro Thr Gln Lys
Gln Ile Asn Val
Gln Ile Val Asn
Gln Lys Pro Thr
Gln Lys Thr Pro
Gln Leu Asn Val
Gln Leu Val Asn
Gln Asn Ile Val
Gln Asn Leu Val
Gln Asn Val Ile
Gln Asn Val Leu
Gln Pro Lys Thr
Gln Pro Thr Lys
Gln Gln Val Val
Gln Thr Lys Pro
Gln Thr Pro Lys
Gln Val Ile Asn
Gln Val Leu Asn
Gln Val Asn Ile
Gln Val Asn Leu
Gln Val Gln Val
Gln Val Val Gln
Arg Asn Pro Ser
Arg Asn Ser Pro
Arg Pro Asn Ser
Arg Pro Ser Asn
Arg Ser Asn Pro
Arg Ser Pro Asn
Ser Asn Pro Arg
Ser Asn Arg Pro
Ser Pro Asn Arg
Ser Pro Arg Asn
Ser Arg Asn Pro
Ser Arg Pro Asn
Thr Lys Pro Gln
Thr Lys Gln Pro
Thr Pro Lys Gln
Thr Pro Gln Lys
Thr Gln Lys Pro
Thr Gln Pro Lys
Val Ala Phe His
Val Ala His Phe
Val Phe Ala His
Val Phe His Ala
Val His Ala Phe
Val His Phe Ala
Val Ile Asn Gln
Val Ile Gln Asn
Val Leu Asn Gln
Val Leu Gln Asn
Val Asn Ile Gln
Val Asn Leu Gln
Val Asn Gln Ile
Val Asn Gln Leu
Val Gln Ile Asn
Val Gln Leu Asn
Val Gln Asn Ile
Val Gln Asn Leu
Val Gln Gln Val
Val Gln Val Gln
Val Val Gln Gln
Tyr Pro Pro Pro
Lucidenic acid K
9a-Acetoxy-7b-hydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-1H-cyclopropa[3,4]benzo[1,2-e]azulen-9-yl (2E)-2-methyl-2-butenoate
ST 24:1;O4;S
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
Sulukast
C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent
Pacritinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EJ - Janus-associated kinase (jak) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C125450 - JAK2 Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Methylprednisolone aceponate
D - Dermatologicals > D07 - Corticosteroids, dermatological preparations > D07A - Corticosteroids, plain > D07AC - Corticosteroids, potent (group iii) C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid D000893 - Anti-Inflammatory Agents
4-N-[4-(4-amino-N-(4-aminophenyl)anilino)phenyl]-4-N-(4-aminophenyl)benzene-1,4-diamine
8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
B5R5IQ1D64
COVID info from PDB, Protein Data Bank Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
7-(3,4-dimethoxyphenyl)-4-methyl-2-[4-(phenylmethyl)-1-piperazinyl]-7,8-dihydro-6H-quinazolin-5-one
(2R,4S)-4-Carbamimidamido-3-acetamido-2-((1R,2R)-2-hydroxy-1-methoxy-3-(octanoyloxy)propyl)-3,4-dihydro-2H-pyran-6-carboxylic acid
3alpha-Sulfooxy-12alpha-hydroxy-5beta-cholan-24-oic acid
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
[13-acetyloxy-1-hydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] (E)-2-methylbut-2-enoate
Homoplatensimide A Methyl Ester
A carboxylic ester of homoplatensimide A isolated from Streptomyces platensis.
(3R,4R)-N-[3-(dimethylamino)propyl]-3-[4-(hydroxymethyl)phenyl]-2-(5-methyl-2-pyridinyl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide
[(1R)-7-methoxy-9-methyl-1-[(5-phenyl-3-isoxazolyl)methyl]-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
1-[[(2R,3S)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2S,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2R,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2S,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2R,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-isoxazolecarboxamide
1-(3-fluorophenyl)-3-[(4S,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4R,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4S,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4S,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
N-[(4S,7S,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4S,7R,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4R,7S,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
1-(3-fluorophenyl)-3-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
[(1S)-7-methoxy-9-methyl-1-[(5-phenyl-3-isoxazolyl)methyl]-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
1-[[(2S,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2S,3S)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-(3-fluorophenyl)-3-[(4S,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4R,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4R,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5R,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
N-[(4R,7R,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4R,7R,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4R,7S,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4S,7S,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4S,7R,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
1-(3-fluorophenyl)-3-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
methyl 2-[(1S,3S,5R,7S,8S,9S,12S,13S)-13-(furan-3-yl)-5-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.01,12.03,8]heptadecan-7-yl]acetate
Laninamivir octanoate
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
Chenodeoxycholic acid 3-sulfate
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
PF-00835231
A primary alcohol resulting from the cleavage of the phosphate group of the prodrug PF-07304814. It is an inhibitor of SARS-CoV-1 and -2 main protease (3CLpro) and exhibits potent in vitro antiviral activity.
LPMe(20:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved